• In-Hwa Choi will become KRPIA's new Policy Director
• by Eo, Yun-Ho Jan 16, 2024 06:08am

• Company
• Reimbursed drugs hit four-year low amid regulatory changes
• by Chon, Seung-Hyun Jan 16, 2024 06:08am

• Company
• 'Discussing Rinvoq based on Korean RWD'
• by Eo, Yun-Ho Jan 15, 2024 05:47am

• InterView
• ‘2nd line opt for CMV is limited…should improve access'
• by Son, Hyung-Min Jan 15, 2024 05:36am

• Company
• Tarlatamab designated as an orphan drug for SCLC
• by Eo, Yun-Ho Jan 15, 2024 05:36am

• Opinion
• [Reporter’s View] HIRA's role in managing high-priced drugs
• by Kim, Jin-Gu Jan 15, 2024 05:36am

• Product
• Shortage no more for Saxenda?...'will increase supply'
• by Kang, Hye-Kyung Jan 15, 2024 05:36am

• Company
• Boryung partners with Baxter for 2 anesthesia drugs in Korea
• by Kim, Jin-Gu Jan 12, 2024 07:06am

• Policy
• AHA drug Obizur to soon receive reimb in Korea
• by Lee, Tak-Sun Jan 12, 2024 07:06am

• Company
• Generic companies partially win Trajenta patent challenges
• by Kim, Jin-Gu Jan 12, 2024 07:06am